Biomarkers Urgently Needed to Advance Treatment Decisions for Pancreatic Ductal Adenocarcinoma
Menée à partir de données génomiques et de données cliniques portant sur 331 patients atteints d'un adénocarcinome canalaire du pancréas (âge médian : 66 ans), cette étude identifie une signature, basée sur deux polymorphismes à simple nucléotide situés au niveau de régions non codantes et fonctionnelles de gènes impliqués dans la régulation de l'évolution de la maladie (progression, invasion, développement de métastases), permettant de prédire la survie après un traitement chirurgical
An important multicenter study by Dimitrakopoulos et al in this issue of JAMA Surgery reports on a genome-wide screening for functional single-nucleotide polymorphisms (SNPs) in patients with pancreatic adenocarcinoma (PDAC). The stated purpose of this study was to determine whether these SNPs could serve as biomarkers of prognosis and direct treatment in PDAC. This is pivotal to the advancement of precision medicine: biomarkers that accurately prognosticate the biological behavior of a patient’s tumor and direct individuated treatment strategies.Rather than focusing on the SNPs themselves, the excellent science behind the work of Dimitrakopoulos et al, the potential of the identified genetic variants to fulfill the role of biomarker, or a comparison of the usefulness of the identified SNPs with other biomarkers (such as tumor antigens, circulating tumor cells, nucleic acids, and exosomes), this Invited Commentary will seek to underscore the urgent task of discovering key biological biomarkers that can be applied in treatment decisions for individual patients. This is especially important as the vast biological heterogeneity of pancreatic adenocarcinoma comes into focus.
JAMA Surgery , commentaire, 2018